



LUND UNIVERSITY

Annexin A2 and A5 serve as new ligands for C1Q on apoptotic cells.

Martin, Myriam; Leffler, Jonatan; Blom, Anna

Published in:
Journal of Biological Chemistry

DOI:
[10.1074/jbc.M112.341339](https://doi.org/10.1074/jbc.M112.341339)

2012

[Link to publication](#)

Citation for published version (APA):
Martin, M., Leffler, J., & Blom, A. (2012). Annexin A2 and A5 serve as new ligands for C1Q on apoptotic cells. *Journal of Biological Chemistry*, 287(40), 33733-33744. <https://doi.org/10.1074/jbc.M112.341339>

Total number of authors:
3

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

ANNEXIN A2 AND A5 SERVE AS NEW LIGANDS FOR C1Q ON APOPTOTIC CELLS

Myriam Martin¹, Jonatan Leffler¹ and Anna M. Blom¹

¹Lund University, Department of Laboratory Medicine Malmö, Medical Protein Chemistry, Inga Marie Nilssons gata 53, S-205 02 Malmö, Sweden

*Running title: *Annexins bind C1q*

To whom correspondence should be addressed: Anna M. Blom; Lund University, Department of Laboratory Medicine Malmö, Medical Protein Chemistry, Inga Marie Nilssons gata 53, S-205 02 Malmö, Sweden; tel: (46) 40 338233, fax: (46) 40 337043, E-mail: Anna.Blom@med.lu.se

Keywords: C1q, complement, apoptosis, annexin A2, annexin A5, SLE

Background: C1q opsonizes apoptotic cells to facilitate clearance.

Results: Annexin A2 and A5 as well as DNA and histones serve as ligands for C1q on apoptotic cells.

Conclusion: Disturbances in the interaction between C1q and these ligands might exacerbate autoimmune diseases.

Significance: The knowledge of new C1q ligands helps to further the understanding of autoimmune diseases.

SUMMARY

C1q is the initiator of the classical complement pathway and opsonizes apoptotic cells to facilitate phagocytosis. Deficiency of C1q is the strongest known risk factor for development of systemic lupus erythematosus (SLE)^a, which appears to be related to ensuing impaired clearance of apoptotic material. The objective of the current study was to investigate new ligands for C1q on the surface of apoptotic cells. We revealed that the two phospholipid-binding proteins annexin A2 and A5 are, beside DNA, significant C1q ligands. We furthermore demonstrated that C1q binds directly to histones exposed on the surface of dying cells but we did not detect significant interaction with phosphatidylserine. The complement inhibitors C4b-binding protein (C4BP) and factor H (FH) also interact with dying cells, most likely to decrease complement activation beyond the level of C3 in order to allow non-inflammatory clearance. Despite the fact that C4BP, FH and C1q share some ligands on dying cells, we showed that these three proteins did not compete with one another for binding to apoptotic cells. We additionally demonstrated that the way in which apoptosis

is induced influenced both the degree of apoptosis and the binding of C1q.

The knowledge, that annexin A2 and A5 act as ligands for C1q on apoptotic cells, sheds new light on the pathophysiology of autoimmune diseases.

The complement system constitutes an integral part of innate immunity and serves as a first line of defence against many pathogens. Besides this, it contributes significantly to clearance of immune complexes and dying cells (1). The classical complement pathway is initiated when the C1-complex binds its target e.g. apoptotic cells, which triggers a cascade of proteolytic cleavages of downstream complement proteins (2). The globular head domains of C1q subunit comprise the recognition units of the C1-complex. There are six head domains to each C1q-molecule and simultaneous binding of several ligands is required for activation of C1. Some C1q ligands are known to bind the N-terminal collagen-like stalk region but these usually do not trigger the classical pathway. C1q binds to surface blebs of apoptotic cells (3) and the interaction is mediated by the globular head region of C1q causing complement activation and deposition of C3b on dying cells (4-7). The aim of the current study was to investigate new ligands for C1q on the surface of apoptotic cells. So far the only widely accepted C1q ligand on dying cells is DNA, which becomes accessible already very early on apoptotic cells, even before phosphatidylserine (PS) (8). However, the precise region of C1q involved in DNA binding is a matter of controversy, since both the collagen-like stalk region and the globular head region have been implicated (7,9-12). C1q has also been proposed to bind PS (13). C1q appears

to bind relatively late apoptotic cells and necrotic cells.

Two complement inhibitors, C4b-binding protein (C4BP) and factor H (FH), have also been shown to interact with apoptotic and necrotic cells (14-16). The binding of C4BP, which circulates mainly in complex with protein S, to dying cells is mediated by interaction of protein S with PS (14) and to a much lesser extent via an interaction of the C4BP α -chains with DNA (16). In comparison, we showed recently that FH binds to annexin A2, DNA and histones on the surface of apoptotic cells (17). These two complement inhibitors interfere with the cascade at the C3 level in order to minimize pro-inflammatory and lytic effects of full-blown complement activation. They also compensate for the loss of membrane-bound complement inhibitors such as membrane cofactor protein (MCP, CD46), which in turn, when down-regulated during apoptosis, act as an “eat-me” signal for effective clearance (8). Efficient and non-inflammatory clearance of dying cells is crucial to avoid autoimmune reactions. Failure to do so, for example in the case of genetic C1q deficiency, is proposed to be one of the underlying mechanisms in systemic lupus erythematosus (SLE). In SLE, autoantibodies directed against antigens present on dying cells are frequently found, which indicates less efficient or pro-inflammatory clearance of effete cells. Reasons for induced inflammatory clearance range from genetic or acquired deficiencies of C1q to potential alterations in ligands for proteins that prevent inflammatory clearance, such as the fluid phase complement inhibitors. Autoantibodies directed against apoptotic cells might further promote an Fc γ R mediated clearance, which is pro-inflammatory. Autoantibodies might also block binding sites for opsonins or complement inhibitors. Autoantibodies directed against annexins have been described in SLE (18).

Annexins are unique proteins that interact with membrane phospholipids in a Ca²⁺-dependent manner, providing a link between Ca²⁺-signaling and membrane functions. The human annexin protein family encompasses over ten members, which are involved in intracellular transport and function as bridging molecules to phospholipid membranes (19). It has been suggested that they play a role in many types of diseases including autoimmune diseases such as SLE (20-22). Annexin A5 is also widely used as

an apoptotic marker since it recognizes PS on the surface of apoptotic cells.

In the current study, we further characterized the proposed binding partners for C1q and C4BP on apoptotic cells, and identified annexin A2 and A5 as new ligands for C1q. This knowledge helps to further the understanding of the pathophysiology of autoimmune diseases such as SLE.

EXPERIMENTAL PROCEDURES

Cells and induction of cell death — Jurkat T-cells (ATCC) were grown in RPMI containing glutamine and 10% heat-inactivated fetal calf serum (all from Invitrogen). Apoptosis was generally induced using 0.75 μ M staurosporine (Sigma) for 16 h in RPMI without fetal calf serum at 37°C and 5% CO₂. Apoptosis was additionally induced for 4 h using: 1 μ M staurosporine, 10 μ M camptothecin, 100 μ M etoposide, 10 μ M actinomycin D or 100 μ M cyclohexamide, all from Calbiochem or anti-fas and protein G (each 1 μ g/ml), from Calbiochem and Sigma, respectively.

Isolation of primary T-lymphocytes — Peripheral blood leukocytes were isolated from leukocyte filters within 5 hours of blood donation. Cells were washed from the filter using PBS with 2 mM EDTA (PBS/EDTA), and peripheral blood mononuclear cells (PBMCs) were isolated by density media centrifugation using Lymphoprep (Axis Shield) according to supplied instructions. Isolated PBMCs were washed twice in PBS/EDTA and total CD4⁺ T cells were purified by positive selection using anti-CD4 coupled magnetic beads (Miltenyi Biotech) according to supplied instructions, with an average purity of over 95%. Isolated CD4⁺ T cells were resuspended in RPMI for further use.

Proteins, antibodies and sera — The C4BP-protein S complex (23), FH (24), C1q (25), protein S (26) and α 1-anti trypsin (27) were purified from human plasma as described. The preparation of stalk and head portions of C1q was performed according to published protocols (28), where pepsin (Worthington) and collagenase (from *Clostridium histolyticum*, Worthington), respectively, were used for partial digestion of C1q. Histones (H2A/H2B+H1 and H3/H4) were purified from Jurkat T-cells (17), human IgG were from Immuno, annexin A2

(437622) was from Calbiochem and annexin A5 (5165871A) from BD Biosciences. All isolated proteins were at least 95% pure, as judged by Coomassie staining of proteins separated by SDS-PAGE. Antibodies used were: anti-dsDNA (21227771, Immunotools), anti-C4BP PK9008 (home made), anti-FH (A312, Quidel), anti-C1q (A0136, Dako), anti-C4c (Q0369, Dako), anti-annexin A2 (ab41803, Abcam) and anti-annexin A5 (ab14196, Abcam). Secondary antibodies: HRP-conjugated were: anti-rabbit (P0399, Dako), anti-goat (P0449, Dako) and fluorescently labeled were: anti-rabbit Alexa Fluor (AF) 647 (A21246, Invitrogen), anti-mouse AF488 (A11059, Invitrogen) and anti-goat AF647 (A21446, Invitrogen). Normal human serum (NHS) and heat-inactivated serum (Hi-NHS) were prepared as described (26) according to permit granted by ethics committee of Lund University. C1q deficient sera (A112) and normal control sera (A509) were purchased from Quidel.

Labeling of proteins with fluorescent dyes — C1q, C4BP and FH were either labeled with AF488 (Invitrogen) or with DyLight 488 (Pierce), respectively, following the manufacturer's instructions. C1q was easily negatively affected by the labeling and therefore sometimes replaced with unlabeled protein followed by detection with antibodies.

Complement deposition and binding assay — For deposition assays, 2.5 µg/ml and for binding assays, 4 µg/ml annexin A2, annexin A5, H2A/H2B+H1 and H3/H4 were coated onto a Maxisorp (Nunc) microtiter plate in 75 mM sodium carbonate buffer pH 9.6 at 4°C over night. Aggregated IgG (2.5 µg/ml for deposition and 2 µg/ml for binding assays) was used as positive control, 1% BSA or 4 µg/ml α1-antitrypsin were used as negative controls. The unbound proteins were washed with 50 mM Tris-HCl, 150 mM NaCl and 0.1% Tween 20, pH 7.5 (immunowash), blocked in 1% BSA (binding assays) or immunowash containing 3% fish gelatin (deposition assays), washed and incubated with either NHS or Hi-NHS in 5 mM veronal buffer with 0.1% gelatin, 1 mM MgCl₂ and 0.15 mM CaCl₂ (GVB++) or purified proteins in 50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 50 µg/ml BSA for 2 h at RT (binding assays) or 25 min at 37°C (deposition assays). For competition studies, the purified proteins were pre-incubated with 5 to 25 molar excess of additional protein for 45 min at RT, in

50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 50 µg/ml BSA, washed, incubated with antibodies specific for C1q, C4c or FH, washed and incubated with appropriate HRP-conjugated secondary antibody and developed using OPD tablets (Dako) according to manufacturer's instructions. Absorbance was measured at 490 nm in a Cary50 Bio UV spectrophotometer connected to a 50MPR microplate reader (Varian). For assessment of ionic strength dependence, the same basic assay was used. However, 10 µg/ml C1q was incubated in binding buffer with NaCl concentrations ranging from 0 to 1000 mM. The binding assay assessing calcium/magnesium dependence was performed using binding buffer supplemented with 5 mM EDTA or 20 mM EDTA.

Binding of radiolabelled proteins to C1q heads and tails — 4 µg/ml purified C1q, C1q globular heads and collagenous tails were coated as above. 1% BSA or 4 µg/ml α1-antitrypsin were used as negative controls. The unbound proteins were washed with immunowash, blocked in 1% BSA and incubated with ¹²⁵I-radiolabelled histones H2A/H2B+H1 and H3/H3 as well as annexin A2 and A5 in 50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM CaCl₂, 50 µg/ml BSA over night (for histones) or 5 h (for annexins) at RT. After washing, the radiolabelled bound proteins were measured using a 1277 GammaMaster (LKB Wallac).

Flow cytometry — For binding or expression analysis by flow cytometry, apoptosis was induced for indicated time points as above. For liposomes, liposome-coated Dynabeads were prepared as described below. For binding experiments, cells or liposomes were washed in 10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂ and 2 mM CaCl₂ (binding buffer) and incubated with unlabeled or labeled proteins. For competition experiments, proteins were pre-incubated for 30 min at RT with competing protein in 5 to 25 molar excess. Proteins in binding buffer were subsequently incubated with cells or liposomes for 30 min at 37°C. For experiments with unlabeled proteins or expression analysis, samples were washed in PBS supplemented with 1% BSA and 30 mM NaN₃, incubated with primary antibody for 30 min, washed, incubated with fluorochrome labeled secondary antibody for 30 min, washed and taken up in binding buffer supplemented with 30 mM NaN₃ and analyzed in a CyFlow

Space (Partec). For discrimination between live, apoptotic or necrotic cells, samples were stained with annexin A5-PE (BD Bioscience) and Via-Probe (BD Bioscience) in binding buffer after antibody staining, incubated 20 min and analyzed as above.

Confocal microscopy — Apoptosis was directly induced on SuperFrostPlus object slides (Menzel). Therefore 80000 cells diluted in RPMI without fetal calf serum containing 1 μ M staurosporine were pipetted within a Dako Pen inked circle and incubated for indicated time at 37°C 5% CO₂. After washing twice with 10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂ and 2 mM CaCl₂ (binding buffer), the proteins were added to the cells in a final volume of 30 μ l and incubated for 30 min at 37°C in a humidified chamber. After washing 3x for 5 min in PBS, the cells were fixed with 3.7% PFA for 15 min, washed again and centrifuged for 1 min at 500 rpm in a Cellspin (Tharmac). After blocking with PBS + 1% BSA + 30 mM NaN₃ for 30 min at 37°C, the primary antibody was incubated either overnight at 4°C or for 1 h at RT. After washing, the cells were incubated with the secondary antibody for 1 h at RT followed by washing and addition of 100 ng/ml propidium iodide (PI) or 50 μ l of AF-labeled annexin A5 diluted 1:2 – 1:6 in 10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl₂, pH 7.4 for 15 min. For annexin A5-staining, the cells were pre-incubated for 30 min and washed with the corresponding Ca²⁺-containing buffer. After the final wash, the slides were briefly dipped in 99% ethanol, dried and mounted with DakoCytomation fluorescent mounting medium. All slides were analyzed in a LSM 510 Meta confocal microscope (Zeiss); co-localization was calculated using CoLocalizer Express (CoLocalization Research Software).

Liposome preparation — All used phospholipids are listed in Table 1. They were purchased from Avanti Polar Lipids and kept in chloroform with 10% methanol at -20°C. For surface plasmon resonance experiments, lipids were mixed in desired molar ratios and the chloroform was removed. Liposomes were generated by extrusion. Lipids were resuspended in 10 mM Hepes pH 7.4 and 150 mM NaCl, frozen and thawed 5 times using dry ice-acetone and 40°C water bath, extruded 19 times through two polycarbonate membranes with 100 nm pores (Avestin) using a LiposoFast-Basic (Avestin) and stored at 4°C for use within 7 days. For flow

cytometric assays, 1 μ mol of lipids in desired molar ratio were mixed with 10 nmol of N-(biotinyl)-1,2-dihexadecanoyl-*sn*-glycero-3-phosphoethanol-amine, triethylammonium (Invitrogen) and 6.4 nmol of 2-(3-(diphenylhexatrienyl)propanoyl)-1-hexadecanoyl-*sn*-glycero-3-phosphocholine (Invitrogen), chloroform was evaporated and lipids were resuspended in 25 mM Hepes and 150 mM NaCl, pH 7.7 (HBS), sonicated and mixed with M-280 streptavidin-coated Dynabeads (Invitrogen) as previously described.

Surface plasmon resonance — To measure the kinetics of DNA – C1q interaction, biotinylated DNA was coupled to a streptavidin-coated SA chip (GE Healthcare). Double-stranded 25-mer oligonucleotides (G-C)₂₅ and (A-T)₂₅ were produced using equimolar amounts of single stranded 5'-biotinylated 25-mer oligonucleotides (MWG) as described (16). Briefly, equal concentrations of G-C and A-T were coupled to the streptavidin sensor chip surface to a level of 300 response units (Biacore 2000, GE Healthcare). All experiments were performed at a continuous flow rate of 30 ml/min using running buffer (150 mM NaCl, 10 mM Hepes, 2.5 mM CaCl₂, 0.002% Tween-20, pH 7.4). C1q was run over the chip in a concentration gradient from 2 to 200 nM. The chip was regenerated using pulse injection of 3 M guanidium chloride followed by 1 M NaCl. The obtained sensograms were analyzed using Bio-evaluation software 3.0 (GE Healthcare).

To measure kinetics of lipid-protein interactions (29) the lipophilic L1 sensor chip was washed for 1 min at flow of 20 ml/min with 40 mM *n*-Octyl- β -D-glucopyranoside (Calbiochem). Phospholipid liposomes (500 mM), generated by extrusion, were injected for 17 min at a 3 ml/min flow rate in HBS running buffer. The average immobilisation level for all liposomes was 1000 RU. The chip was then washed five times with 10 mM EDTA (pH 8.0) injections (2 min at 20 ml/min), after which the membrane surface was stable. For protein binding experiments, running buffer was changed to HBC (HBS with 10 mg/ml BSA and 5 mM CaCl₂) and flow cells were equilibrated until the baseline stabilized. Purified C1q and C4BP were diluted in HBC and injected over the liposome surfaces at several serial dilutions ranging from 400 to 6 mg/ml. The flow was set at 20 ml/min and the proteins were allowed to associate for 240 sec followed by 200 sec dissociation. The immobilized liposome surface

could be regenerated with an injection of 10 mM EDTA (pH 8.0), which returned the baseline to the value prior to introducing protein. To calculate the dissociation constant (K_D) of interaction between C4BP and liposomes containing 90% PC / 10% PS the response obtained at equilibrium was plotted against each concentration used and the one-site binding hyperbola was fitted using Prism (GraphPad).

RESULTS

C1q binds to late apoptotic cells and interacts with DNA and histones — DNA has been previously suggested to act as C1q ligand on apoptotic cells (8). To further investigate the relevance of this interaction, surface plasmon resonance was used to analyze the binding affinity between C1q and DNA (Fig. 1A-B). Biotinylated DNA was immobilized onto a streptavidin chip and C1q was injected at several concentrations. K_D derived from the plot of response at equilibrium versus C1q concentration was estimated to 2.2×10^{-8} M and indicates very strong binding between the two molecules.

To validate the interaction of C1q and DNA on apoptotic cells, C1q was incubated with apoptotic Jurkat T-cells and the amount of bound C1q as well as available DNA were assessed using an antibody against dsDNA. C1q did not bind to live Jurkat cells but did bind to apoptotic cells that were induced with $0.75 \mu\text{M}$ staurosporine for at least 6 h (Fig. 1C). Very weak or no binding occurred to apoptotic cells, which were induced for shorter time whereas the binding increased with longer induction times (up to 16 h). C1q bound to both the A5+/Via-Probe- (early apoptotic) and A5+/Via-Probe+ (late apoptotic/necrotic) populations of cells induced for at least 6 h, whereby it bound stronger to the double positive cells. After 16 h of incubation approximately 45% of the cells were A5+/Via-Probe- and 45% A5+/Via-Probe+. In order to exclude that serum deprivation alone led to induction of C1q binding, we tested binding to cells that have been incubated for 16 h in RPMI without addition of staurosporine. Almost no cells were A5+ or Via-Probe+ indicating that C1q binding is induced by apoptosis (data not shown).

With the apoptosis induction procedure used in this study, an elevated surface level of DNA was detected 4 h after apoptosis induction and increased strongly with longer induction times (Fig. 1C). This indicates that DNA is present on

the surface before C1q starts to bind. Together with the observation that the elevated surface level of DNA rises more strongly than C1q binding, we assumed that DNA can not be the only C1q ligand on dying cells or that the cell surface must be reorganized before DNA is available for interaction with C1q.

In order to visualize and confirm the interaction of C1q and DNA on the surface of apoptotic cells, confocal microscopy was performed (Fig. 1D). Co-localization was calculated for different areas on two microscope slides from separate experiments by using the overlap coefficient (R) according to Manders (30). C1q and DNA displayed a mean coefficient of 0.74 ± 0.04 , which clearly indicates co-localization.

DNA can be present as nucleosomes on the surface of apoptotic cells (31) and therefore we tested whether C1q could interact directly with histones. The interaction was evaluated using purified histones from Jurkat T-cells in an ELISA setup. Clear binding of purified C1q to both H2A/H2B+H1 and H3/H4 histones was observed (Fig. 1E). This interaction was also detected from heat inactivated serum; Hi-NHS (Fig. 1F). In order to verify whether histones bind to the globular head or to the collagenous tail region of C1q, proteins were immobilized and incubated with radiolabelled histones. Both histone fractions bound mainly to the collagenous tail region of C1q but binding to the globular head region was also significant (Fig. 1G and H). Interaction of histones with C1q could result in both inhibition and activation of complement depending on the C1q region involved in the interaction. Therefore immobilized histones were incubated with NHS and deposition of C4b was detected using specific antibodies. Both histone pairs induced strong complement activation (Fig. 1I). To evaluate if C1q was responsible for the observed activation, histones were incubated with C1q deficient NHS and C1q deficient NHS reconstituted with $70 \mu\text{g/ml}$ purified C1q. While no deposition was seen in the absence of C1q, surprisingly only histones H3/H4 were able to induce C4b deposition upon reconstitution (Fig. 1J). This indicates the presence of other activating factors in NHS that are lacking in the C1q deficient serum.

Purified annexins A2 and A5 bind C1q and activate the classical pathway of complement — A direct binding assay was used to assess interactions of purified C1q with annexins A2

and A5 immobilized in microtiter plates. C1q bound specifically in a dose-dependent and saturable manner (Fig. 2A), whereby the binding to annexin A2 was stronger than to annexin A5. Aggregated IgG was used as a positive control and α 1-antitrypsin as a negative control for C1q binding. In order to confirm that C1q from serum binds to annexin A2 and A5, the binding experiment was repeated using NHS as C1q source. Binding to both proteins was confirmed in NHS. The binding of C1q from serum to annexin A5 was comparable to the binding obtained with purified C1q. However, the binding to A2 from serum was much weaker than that of purified C1q (Fig. 2B). This indicates that either the serine proteases C1r and C1s, which are present in the C1 complex or some other serum proteins attenuate the interaction between C1q and annexin A2.

To evaluate the nature of the C1q-annexin A2 and A5 binding, C1q was incubated with immobilized annexins in buffers of varying ionic strength. Both interactions were of ionic nature and the interaction of C1q to A5 was more sensitive to the present ionic strength (Fig. 2C). Furthermore, neither the binding of C1q to annexin A2 nor to annexin A5 was dependent on the presence of calcium and magnesium ions (Fig. 2D). Both radiolabelled annexin A2 and A5 bound weaker to C1q heads in comparison to the collagenous tail region (Fig. 2E and F). This difference was more pronounced for annexin A2 compared to annexin A5.

We showed recently that annexin A2 is one of the ligands localizing FH to the surface of apoptotic cells (17). Therefore competition experiments were performed whereby annexin A2 was immobilized in microtiter plates and binding of C1q and FH, respectively, was evaluated in the presence of no, five- or 25-fold molar excess of the other protein. Protein and competitor were pre-incubated at room temperature. Neither FH (Fig. 2G) nor C1q (Fig. 2H) competed with the other protein for the binding to immobilized annexin A2.

To assay the complement activating potential of the annexins, immobilized annexin A2 and A5 were incubated with NHS as a source of complement and deposition of C4b was detected using specific antibodies. Both annexin A2 and A5 induced complement activation, where activation by annexin A5 was comparable to the strongly activating aggregated IgG (Fig. 2I). The requirement of C1q for complement activation to occur was confirmed using C1q

deficient NHS as well as reconstituted C1q deficient NHS. No deposition of C4b was observed for IgG or the two annexins from C1q deficient NHS, but could be fully restored upon addition of C1q (Fig. 2J).

C1q binds to apoptotic T- and B-cells and interacts with annexin A2 and A5 exposed on the cell surface — C1q bound dose-dependently to apoptotic Jurkat T-cells and Namalwa B-cells (Fig. 3A and B). No significant differences were found when binding of C1q to apoptotic cells was evaluated at RT for 2 h compared to incubations at 4°C for 2 h or at 37°C for 30 min. The incubation at 37°C for 30 min was chosen for all following experiments. Using this setup, C1q bound dose-dependently to apoptotic primary T-lymphocytes, although the binding reached lower levels compared to Jurkat T-cells (Fig. 3C). Both annexin A2 and A5 were only present in negligible amount on the cell surface of live Jurkat T-cells but both proteins became exposed during the course of apoptosis induction (Fig. 3D). The same course of expression was detected on Namalwa B-cells (data not shown). C1q bound to both annexins when purified proteins were used (Fig. 2A) and thus we investigated whether externally added annexin A2 or A5 could affect the binding of C1q to apoptotic cells. Both proteins were able to increase the binding of C1q to the cell surface, confirming interaction in a setting of the whole cell membrane (Fig. 3E and F). Due to the fact that both annexins bind to negatively charged phospholipids, which become exposed on the cell surface during apoptosis, it was expected that these proteins, when pre-incubated with C1q, localize even more C1q to the cell membrane.

C1q, C4BP and FH do not compete for one another's binding to apoptotic cells — C1q, C4BP and FH have all been proven to bind to apoptotic cells (3,14,15). In order to clarify whether they influence one another's binding, competition assays were performed. Jurkat T-cells were rendered apoptotic and incubated for 30 min with either 25 μ g/ml C1q, 15 μ g/ml C4BP-AF488 or 5 μ g/ml FH-AF488 either alone or in the presence of five- or 25-fold molar excess of each of the other proteins separately. The protein and potential competitor were pre-incubated for 30 min at RT before the addition to the cells. Neither C4BP (Fig. 4B) nor FH (Fig. 4C) competed with C1q binding and neither did C1q compete with C4BP (Fig. 4D) or FH binding (Fig. 4E). In order to verify that the

experimental settings were correct, C4BP (25 $\mu\text{g/ml}$) was also incubated with five- and 25-fold molar excess of annexin A5. Both C4BP and annexin A5 bind strongly to negatively charged phospholipids, and annexin A5 was indeed able to compete with C4BP in a statistically significant manner for the binding of apoptotic Jurkat cells at a five-fold molar excess (Fig. 4A).

C1q does not interact with phospholipids — In order to clarify whether C1q interacts with phospholipids that might be present on the surface of apoptotic cells, surface plasmon resonance was performed using different compositions of extruded liposomes immobilized on an L1 chip. C1q or C4BP, used as a positive control, were injected at different concentrations. During the course of apoptosis, endogenous phospholipases are activated that generate lysophospholipids on the apoptotic cell surface (32). Lipid oxidation also occurs during the onset of programmed cell death (33). Therefore C1q binding to different compositions of lysophospholipids and oxidized phospholipids was also investigated. All tested liposome compositions are listed in Table 1. We found that purified C1q bound to none of the tested liposomes (data not shown). C4BP on the other hand, as expected, bound strongly to liposomes containing 10% PS, whereby it bound slightly better to natural PS (Fig. 5A) than to synthetic PS (Fig. 5B). The binding constants were determined as 1.09×10^{-7} and 1.93×10^{-7} M to natural and synthetic PS containing liposomes, respectively. It bound equally strongly to oxidized and to non-oxidized synthetic PS (Fig. 5C). Phosphatidylcholine (PC) alone (100%) was used as a negative control. C4BP did not interact with lysoPS, which has not been previously reported.

In order to confirm the results with a different method, liposome-coated Dynabeads were used for flow cytometry analysis. Binding of C1q-AF488 (150 $\mu\text{g/ml}$) and C4BP-AF488 (50 $\mu\text{g/ml}$) to PE/PC (20/80 mol %) and PS/PE/PC (10/20/70 mol %) liposome-coated Dynabeads was determined. As expected, C4BP bound strongly to the PS-containing liposomes, whereas C1q, even when applied in a three times higher concentration, did not bind to these liposomes (Fig. 5D). The signal obtained from the PE/PC liposomes was defined as background binding and set to 1.

Confocal microscopy was performed to visualize C1q and PS on the surface of apoptotic

cells, whereby AF647-labeled A5 was used to stain PS, and PI to counter stain nucleic DNA (Fig. 5E). Potential co-localization was calculated for different areas on two microscope slides from separate experiments and the mean overlap coefficient was determined to 0.51 ± 0.06 , indicating no significant co-localization for C1q and PS. A time course experiment, using the same time points as displayed in Figure 1, was performed to determine the overlap coefficient for the whole course of apoptosis induction. The overlap coefficient for live cells was 0.14 ± 0.04 and increased with time up to 0.51 ± 0.06 for the 16 h induced cells, indicating perhaps that C1q localized close to PS with the increasing apoptosis but that the two ligands never co-localized strongly.

Comparison of different apoptosis inducers and their impact on C4BP, FH and C1q binding — In order to see whether the mode of apoptosis induction influences the binding of C4BP, FH and C1q to apoptotic cells, Jurkat T-cells were stimulated with commonly used concentrations of different inducers of the intrinsic (staurosporine, etoposide and camptothecin) or the extrinsic (anti-fas Ab, cycloheximide, actinomycin D) apoptosis induction pathway. The histograms in Fig. 6 display the binding of C4BP (A), C1q (B) and FH (C) to the whole populations of cells induced to become apoptotic with various agents. The numbers next to the histograms indicate the percentage of early apoptotic cells in the whole cell population. C4BP bound well to all apoptotic cells irrespectively of inducing agent. However, the binding to α -fas Ab, cycloheximide, actinomycin D and etoposide-induced cells was weaker than to camptothecin and staurosporine-induced cells. Apart from the staurosporine treated cells, for which two peaks appeared in the histogram, only one peak corresponding to bound C4BP was observed for all other inducers (Fig. 6A). C1q bound generally weaker than C4BP and almost no binding could be detected to the anti-fas Ab and very little binding to the actinomycin D and etoposide induced cells (Fig. 6B). Only one peak appeared in the histogram for those cells while two peaks were present for the camptothecin and cycloheximide-induced cells and even three peaks for the staurosporine-induced cells. These may be corresponding to two or three distinct cell populations that vary in their ability to bind C1q. FH bound well to all

apoptotic cells irrespectively of the induction method (Fig. 6C), whereby the anti-fas Ab-induced cells appeared as one homogenous population (one peak in the histogram). The camptothecin, cycloheximide and etoposide-induced cells were divided into two distinct populations (two peaks) and the staurosporine-induced three distinct populations (three peaks). In general all three proteins bound strongest to staurosporine-induced cells and weakest to anti-fas Ab-induced cells. However no specific difference in binding strength could be observed between extrinsic or intrinsic apoptosis inducers. None of the three studied proteins bound to live Jurkat cells (data not shown). In order to verify whether observed different peaks correspond to different stages of apoptosis, the peaks were classified as low, middle or high intensity binding. Staining with annexin A5 and Via-Probe allowed the differentiation into live (A5-/Via-Probe-), early apoptotic (A5+/Via-Probe-) and late apoptotic (A5+/Via-Probe+) populations, which are depicted in the dot plots (only for the staurosporine-induced cells). The cells that bound with high intensity (red) to C4BP, C1q and FH were, as expected, mainly the late apoptotic population. The cells that bound with middle intensity (yellow) to C1q and FH were mainly the early apoptotic population and the cells that bound with low intensity (green) were heterogeneously averaged through all three populations. The percentage of live, early and late apoptotic cells for all inducers are indicated in Fig. 6D. After 4 h stimulation with the different inducers, between 30 and 60% early apoptotic and around 10% late apoptotic cells were detected. Staurosporine was the only exception yielding here approximately 35% late apoptotic cells and thus less than 10% live cells.

DISCUSSION

Proper clearance of apoptotic cells is crucial in order to secure homeostasis. For this purpose, a complex and multifaceted system has evolved containing a vast range of recognition mechanisms of the apoptotic cells from down regulation of “do not eat me” signals to up regulation of “find me” as well as “eat me” signals. Deficiencies of key components of this complex network such as C1q as well as phagocytic receptors decrease the efficiency of clearance, causing apoptotic cells to lose their integrity before being properly cleared. This in turn leads to a more inflammatory environment, which could induce the formation of

autoantibodies paving the path for development of autoimmunity.

C1q has been shown to interact with apoptotic cells both directly (7), which is the subject of this study, and indirectly via C-reactive protein (CRP) (34), serum amyloid P, pentraxin 3 (35) and natural IgM (36). DNA has long been known as a ligand for C1q and here we further characterized the interaction by determining the K_D value using surface plasmon resonance, confirming a very strong interaction. However, due to the fact that C1q binds at a later stage to apoptotic cells than DNA becomes present on their surface and with different kinetics over induction time, we hypothesized that there must be other ligands. Histones are present on apoptotic cells in form of nucleosomes. The pentraxins CRP and serum amyloid P have been shown to bind to histones and activate the classical complement pathway (37). Here we showed that C1q also binds directly to histones, which leads to complement activation. C4b deposition on all histone complexes was abolished in C1q deficient sera but surprisingly it could not be restored upon addition of C1q for the histone complex H2A/H2B+H1, even though deposition was restored for both IgG and H3/H4. This indicates that there is a factor additional to C1q lacking in the C1q deficient sera, which is required for complement activation by C1q on the H2A/H2B+H1 complex, which is not needed for complement activation on H3/H4. We further assayed MBL, factor D, COLEC11 as well as ficolin-L and ficolin-H activity in the different sera, but all tested proteins were functional in both C1q deficient sera and in the control sera (not shown). The importance of the interaction between C1q and nucleosomes (DNA and histones) on apoptotic cells is underscored by the observation that patients with low serum levels of immune complex-containing DNA at the onset of a flare developed a more severe flare compared to patients for whom the level remained stable. This coincided with low C1q serum levels and high disease activity and was not seen among patients with normal levels of C1q at flare (38).

C1q bound dose-dependently to Jurkat T- and Namalwa B-cells with the binding not becoming completely saturated at concentrations used. We revealed that there are at least four different and abundant ligands for C1q on the surface of apoptotic cells. The surface expression of annexins A2 and A5, DNA and

histones increases during the course of apoptosis induction. Hence the overall concentration of possible ligands for C1q is very high on 16 h induced cells and it is likely that the binding can not be fully saturated unless very high concentrations are used. The binding of C1q to primary T-lymphocytes was also dose-dependent, almost saturated and reaching lower levels than for Jurkat T-cells. Primary T-lymphocytes are much smaller than Jurkat T-cells and thus exhibit a lesser total amount of ligands for C1q. As a consequence, the molar ratio of C1q to C1q ligands is larger and the binding saturates at lower concentrations.

Annexin A2 and A5 are both present in serum (39,40) and can bind negatively charged phospholipids. Additionally, their surface expression on lymphocytes increases during apoptosis. C1q preincubated with annexins therefore bound stronger to the apoptotic cell surface and this might be relevant also in an *in vivo* situation. Depending on the apoptosis stage, annexins A2 and A5 co-localized with C1q on some cells, most likely the later apoptotic ones. No co-localization was found on another population of cells, which comprises most likely the early apoptotic ones (data not shown).

PS has been reported to function as a C1q ligand (13), but we could not find experimental evidence for this hypothesis in our assays. Using annexin A5, we found PS already exposed on the cell surface at an early time point (~1 h) after apoptosis induction and detected further increase with induction time up to 4 h. After this time point, almost no further elevation was detected (data not shown). C1q binding occurred significantly later and increased further over the whole induction time. Additionally, we did not detect any interaction of C1q with PS included in liposomes that were immobilized either on L1 chips in Biacore or on beads and analyzed by flow cytometry. The positive control, C4BP-protein S complex bound as expected to PS. Finally, we did not detect significant co-localization of C1q and PS on apoptotic cells at various time points of apoptotic cell induction from early to late apoptotic cells. If C1q bound PS on apoptotic cells we would expect that C1q could compete with C4BP (or the reverse) for binding to apoptotic cells, as A5 does. However, no such competition could be observed. In the same set up, we did not see any competition for C1q with FH, which is in concordance with a recent report (41). The discrepancies with the study by Paidassi et al. (13) might arise from

technical differences since that study employed HeLa cells, an epithelial carcinoma cell line, induced to become apoptotic using UV irradiation. HeLa cells were trypsinized for the experiments and it must be kept in mind that trypsination might have removed protein ligands for C1q on the surface. In addition, liposomes containing 100 % PS, PE or PC were used to study binding of C1q by surface plasmon resonance. This approach is less accurate than our employed mixtures of PC with PS and PE, because even though PS appears in patches on the surface of apoptotic cells, there are always other lipids present. In addition, while the confocal pictures presenting co-localization between C1q and PS looked very convincing, no appropriate software was used to objectively quantify the degree of co-localization. Our software analysis of images found no significant co-localization. An inhibitory effect of annexin A5 on the binding of C1q was also determined, after cells were pre-incubated with annexin A5 and then C1q was applied. We on the other hand pre-incubated the two proteins together and then added the mixture to the cells and thus detected increased C1q binding, possibly due to a bridging function of annexin A5 in guiding bound C1q to negatively charged phospholipids.

Furthermore, we found no interaction of C1q with oxidized liposomes, which are normally found on apoptotic cells (33) or myeloperoxidase-treated apoptotic cells. Inclusion of lysoPS in liposomes did not generate C1q binding but abolished the binding of the C4BP-protein S, which binds with high affinity to PS. Interestingly, the interaction of C4BP-protein S to PS was not affected by oxidation of the lipids, which is in contrast to what has been observed for free, recombinant protein S (42).

Association of inherited C1q deficiency and SLE is very strong, but it is also very rare and thus not responsible for the majority of SLE cases. It is therefore possible that there are other factors preventing interaction of C1q with apoptotic cells in SLE patients, such as autoantibodies to C1q ligands. Interestingly, autoantibodies to both annexin A2 and annexin A5 (21,22) as well as to other C1q ligands and C1q itself (43,44) have been found in patients suffering from autoimmune diseases such as SLE. These antibodies could either decrease direct binding of C1q to apoptotic cells or recruit additional C1q. Both scenarios could lead to an imbalance in complement activation, which

could result in either insufficient removal of the cells or excessive complement activation resulting in a pro-inflammatory environment. Both are commonly seen in SLE.

The fact that C1q deficiency is a much stronger genetic risk factor for development of SLE than deficiency of C4 or C2 (45) suggests that C1q has unique function in addition to initiation of complement leading to the opsonisation with C3b. To support this, evidence has been presented supporting the role of C1q in development of tolerance (46), clearance of immune complexes (47) and cytokine regulation (48). It differentially modulates the phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells as well as of apoptotic neurons by microglia (49,50). Clearly, C1q has many functions crucial for homeostasis and prevention of SLE. Accordingly, low serum level of C1q correlates with severe active SLE (51).

Apoptosis can be induced by two distinct pathways, the intrinsic and the extrinsic. It has been shown that percentage of generated early and late apoptotic cells depends on the inducing agent. This on the other hand influences among others the amount of released DNA by Jurkat T-cells and monocytic U937 cells (52). Lesional late-stage scleroderma fibroblasts have been shown to be relatively resistant to Fas-induced apoptosis, but sensitive to intrinsic induction (53). In the current study we found that the method of inducing apoptosis did influence the binding of C1q and the complement inhibitors, C4BP and FH to apoptotic Jurkat T-cells. All three proteins bound to the majority of apoptotic cells independently of the route of apoptosis induction although the intensity of binding differed strongly. Furthermore, no general

difference was observed between intrinsic or extrinsic inducers and the order of binding strength with which all three proteins bound to the differently induced cells was the same, even though all three proteins bind at least partially to different ligands and did not compete for one another's binding. Jurkat T-cells are transformed cells and the results obtained might be different for primary cells. Some apoptosis inducers generated cells that bound C1q with high, middle and/or low intensity. As expected, the late apoptotic cells mainly bound C1q with high intensity and a quite homogenous population of early apoptotic cells bound with middle intensity. Interestingly, the low intensity binding cells were averaged heterogeneously through the live, early and late apoptotic populations. This indicates that it is not sufficient for a cell to become apoptotic (as determined by annexin A5 and Via-Probe staining) in order to bind C1q and that, other surface changes also must occur to induce C1q binding. Such changes may involve increased surface expression and spatial organization of endogenous annexin A2, A5, DNA or histones or of yet unknown additional ligands.

In conclusion, the current study further characterizes the interactions of complement and apoptotic cells and reveals two members of the annexin family, annexin A2 and A5, as new ligands for C1q on dying cells. This phenomenon gives a further explanation for the observations of the presence of pathologic annexin autoantibodies in SLE. This study hence sheds new light on the interactions underlying complement-mediated clearance of apoptotic cells and helps to further the understanding of the pathophysiology of autoimmune diseases such as SLE.

REFERENCES

1. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Complement, a key system for immune surveillance and homeostasis. *Nat. Immunol.* 11, 785–797
2. Wallis, R., Mitchell, D. A., Schmid, R., Schwaeble, W. J., and Keeble, A. H. (2010) Paths reunited. Initiation of the classical and lectin pathways of complement activation. *Immunobiology* 215, 1–11
3. Korb, L. C., and Ahearn, J. M. (1997) C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. Complement deficiency and systemic lupus erythematosus revisited. *J. Immunol.* 158, 4525–4528
4. Ogden, C. A., deCathelineau, A., Hoffmann, P. R., Bratton, D., Ghebrehiwet, B., Fadok, V. A., and Henson, P. M. (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. *J. Exp. Med.* 194, 781–795

5. Navratil, J. S., Watkins, S. C., Wisnieski, J. J., and Ahearn, J. M. (2001) The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. *J. Immunol.* 166, 3231–3239
6. Vandivier, R. W., Ogden, C. A., Fadok, V. A., Hoffmann, P. R., Brown, K. K., Botto, M., Walport, M. J., Fisher, J. H., Henson, P. M., and Greene, K. E. (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro. Calreticulin and CD91 as a common collectin receptor complex. *J. Immunol.* 169, 3978–3986
7. Nauta, A. J., Trouw, L. A., Daha, M. R., Tijmsa, O., Nieuwland, R., Schwaeble, W. J., Gingras, A. R., Mantovani, A., Hack, E. C., and Roos, A. (2002) Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. *Eur. J. Immunol.* 32, 1726–1736
8. Elward, K., Griffiths, M., Mizuno, M., Harris, C. L., Neal, J. W., Morgan, B. P., and Gasque, P. (2005) CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. *J. Biol. Chem.* 280, 36342–36354
9. Jiang, H., Cooper, B., Robey, F. A., and Gewurz, H. (1992) DNA binds and activates complement via residues 14–26 of the human C1q A chain. *J. Biol. Chem.* 267, 25597–25601
10. Kishore, U., Gupta, S. K., Perdikoulis, M. V., Kojouharova, M. S., Urban, B. C., and Reid, K. B. (2003) Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. *J. Immunol.* 171, 812–820
11. Palaniyar, N., Nadesalingam, J., Clark, H., Shih, M. J., Dodds, A. W., and Reid, K. B. (2004) Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. *J. Biol. Chem.* 279, 32728–32736
12. Tissot, B., Daniel, R., and Place, C. (2003) Interaction of the C1 complex of complement with sulfated polysaccharide and DNA probed by single molecule fluorescence microscopy. *Eur. J. Biochem.* 270, 4714–4720
13. Païdassi, H., Tacnet-Delorme, P., Garlatti, V., Darnault, C., Ghebrehiwet, B., Gaboriaud, C., Arlaud, G. J., and Frachet, P. (2008) C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. *J. Immunol.* 180, 2329–2338
14. Webb, J. H., Blom, A. M., and Dahlbäck, B. (2002) Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. *J. Immunol.* 169, 2580–2586
15. Trouw, L. A., Bengtsson, A. A., Gelderman, K. A., Dahlbäck, B., Sturfelt, G., and Blom, A. M. (2007) C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. *J. Biol. Chem.* 282, 28540–28548
16. Trouw, L. A., Nilsson, S. C., Gonçalves, I., Landberg, G., and Blom, A. M. (2005) C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. *J. Exp. Med.* 201, 1937–1948
17. Leffler, J., Herbert, A. P., Norström, E., Schmidt, C. Q., Barlow, P. N., Blom, A. M., and Martin, M. (2010) Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. *J. Biol. Chem.* 285, 3766–3776
18. Iaccarino, L., Ghirardello, A., Canova, M., Zen, M., Bettio, S., Nalotto, L., Punzi, L., and Doria, A. (2011) Anti-annexins autoantibodies. Their role as biomarkers of autoimmune diseases. *Autoimmun. Rev.* 10, 553–558
19. Gerke, V., Creutz, C. E., and Moss, S. E. (2005) Annexins, linking Ca²⁺ signalling to membrane dynamics. *Nat. Rev. Mol. Cell. Biol.* 6, 449–461
20. Hayes, M. J., and Moss, S. E. (2004) Annexins and disease. *Biochem. Biophys. Res. Commun.* 322, 1166–1170
21. Ao, W., Zheng, H., Chen, X. W., Shen, Y., and Yang, C. D. (2011) Antiannexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis. *Rheumatol. Int.* 31, 865–869
22. Hrycek, A., and Cieślik, P. (2012) Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus. *Rheumatol. Int.* 32, 1335–1342
23. Dahlbäck, B. (1983) Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. *Biochem. J.* 209, 847–856

24. Blom, A. M., Kask, L., and Dahlbäck, B. (2003) CCP1–4 of the C4b-binding protein α -chain are required for factor I mediated cleavage of complement factor C3b. *Mol. Immunol.* 39, 547–556
25. Tenner, A. J., Lesavre, P. H., and Cooper, N. R. (1981) Purification and radiolabeling of human C1q. *J. Immunol.* 127, 648–653
26. Kask, L., Trouw, L. A., Dahlbäck, B., and Blom, A. M. (2004) The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. *J. Biol. Chem.* 279, 23869–23873
27. Laurell, C. B., Dahlqvist, I., and Persson, U. (1983) The use of thiol-disulfide exchange chromatography for the automated isolation of α 1-antitrypsin and other plasma proteins with reactive thiol groups. *J. Chromatogr.* 278, 53–61
28. Pâques, E. P., Huber, R., Priess, H., and Wright, J. K. (1979) Isolation of the globular region of the subcomponent q of the C1 component of complement. *Hoppe-Seyler's Z. Physiol. Chem.* 360, 177–183
29. Krisinger, M. J., Guo, L. J., Salvagno, G. L., Guidi, G. C., Lippi, G., and Dahlbäck, B. (2009) Mouse recombinant protein C variants with enhanced membrane affinity and hyper-anticoagulant activity in mouse plasma. *FEBS J.* 276, 6586–6602
30. Manders, E. M., Verbeek, F. J., and Aten, J. A. (1993) Measurement of colocalization of objects in dual-color confocal images. *J. Microsc.* 169, 375–382
31. Radic, M., Marion, T., and Monestier, M. (2004) Nucleosomes are exposed at the cell surface in apoptosis. *J. Immunol.* 172, 6692–6700
32. Taketo, M. M., and Sonoshita, M. (2002) Phospholipase A2 and apoptosis. *Biochim. Biophys. Acta* 1585, 72–76
33. Buttke, T. M., and Sandstrom, P. A. (1994) Oxidative stress as a mediator of apoptosis. *Immunol. Today* 15, 7–10
34. Mihlan, M., Stippa, S., Józsi, M., and Zipfel, P. F. (2009) Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. *Cell Death Differ.* 16, 1630–1640
35. Nauta, A. J., Bottazzi, B., Mantovani, A., Salvatori, G., Kishore, U., Schwaeble, W. J., Gingras, A. R., Tzima, S., Vivanco, F., Egido, J., Tijmsma, O., Hack, E. C., Daha, M. R., and Roos, A. (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. *Eur. J. Immunol.* 33, 465–473
36. Chen, Y., Park, Y. B., Patel, E., and Silverman, G. J. (2009) IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. *J. Immunol.* 182, 6031–6043
37. Hicks, P. S., Saunero-Nava, L., Du Clos, T. W., and Mold, C. (1992) Serum amyloid P component binds to histones and activates the classical complement pathway. *J. Immunol.* 149, 3689–3694
38. Bengtsson, A., Nezhlin, R., Shoenfeld, Y., and Sturfelt, G. (1999) DNA levels in circulating immune complexes decrease at severe SLE flares. Correlation with complement component C1q. *J. Autoimmun.* 13, 111–119
39. Ji, N. Y., Park, M. Y., Kang, Y. H., Lee, C. I., Kim, D. G., Yeom, Y. I., Jang, Y. J., Myung, P. K., Kim, J. W., Lee, H. G., Lee, K., and Song, E. Y. (2009) Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. *Int. J. Mol. Med.* 24, 765–771
40. Matsuda, R., Kaneko, N., Kikuchi, M., Chiwaki, F., Toda, M., Ieiri, T., Horikawa, Y., Shimizu, M., and Shimamoto, K. (2003) Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. *Resuscitation* 57, 171–177
41. Kang, Y. H., Urban, B. C., Sim, R. B., and Kishore, U. (2012) Human complement factor H modulates C1q-mediated phagocytosis of apoptotic cells. *Immunobiology* 217, 455–464
42. Baroni, M., Pavani, G., Marescotti, D., Kaabache, T., Borgel, D., Gandrille, S., Marchetti, G., Legnani, C., D'Angelo, A., Pinotti, M., and Bernardi, F. (2010) Membrane binding and anticoagulant properties of protein S natural variants. *Thromb. Res.* 125, e33–39
43. Trouw, L. A., and Daha, M. R. (2005) Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. *Expert Opin. Biol. Ther.* 5, 243–251

44. Shoenfeld, Y., Szyper-Kravitz, M., Witte, T., Doria, A., Tsutsumi, A., Tatsuya, A., Dayer, J. M., Roux-Lombard, P., Fontao, L., Kallenberg, C. G., Bijl, M., Matthias, T., Fraser, A., Zandman-Goddard, G., Blank, M., Gilburd, B., and Meroni, P. L. (2007) Autoantibodies against protective molecules, C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1. Prevalence in systemic lupus erythematosus. *Ann. N.Y. Acad. Sci.* 1108, 227–239
45. Truedsson, L., Bengtsson, A. A., and Sturfelt, G. (2007) Complement deficiencies and systemic lupus erythematosus. *Autoimmunity* 40, 560–566
46. Baruah, P., Simpson, E., Dumitriu, I. E., Derbyshire, K., Coe, D., Addey, C., Dyson, J., Chai, J. G., Cook, T., Scott, D., and Botto, M. (2010) Mice lacking C1q or C3 show accelerated rejection of minor histocompatible skin grafts and resistance to induction of tolerance. *Eur. J. Immunol.* 40, 1758–1767
47. Davies, K. A., Hird, V., Stewart, S., Sivolapenko, G. B., Jose, P., Epenetos, A. A., and Walport, M. J. (1990) A study of in vivo immune complex formation and clearance in man. *J. Immunol.* 144, 4613–4620
48. Lood, C., Gullstrand, B., Truedsson, L., Olin, A. I., Alm, G. V., Rönnblom, L., Sturfelt, G., Eloranta, M. L., and Bengtsson, A. A. (2009) C1q inhibits immune complex-induced interferon- α production in plasmacytoid dendritic cells. A novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. *Arthritis Rheum.* 60, 3081–3090
49. Fraser, D. A., Laust, A. K., Nelson, E. L., and Tenner, A. J. (2009) C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. *J. Immunol.* 183, 6175–6185
50. Fraser, D. A., Pisalyaput, K., and Tenner, A. J. (2010) C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production. *J. Neurochem.* 112, 733–743
51. Sturfelt, G., Johnson, U., and Sjöholm, A. G. (1985) Sequential studies of complement activation in systemic lupus erythematosus. *Scand. J. Rheumatol.* 14, 184–196
52. Choi, J. J., Reich, C. F., 3rd, and Pisetsky, D. S. (2004) Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. *Scand. J. Immunol.* 60, 159–166
53. Chabaud, S., Corriveau, M. P., Grodzicky, T., Senécal, J. L., Chartier, S., Raymond, Y., and Moulin, V. J. (2011) Decreased secretion of MMP by nonlesional late-stage scleroderma fibroblasts after selection via activation of the apoptotic Fas-pathway. *J. Cell. Physiol.* 226, 1907–1914

Acknowledgments — We thank Dr. L. A. Trouw for help with the Biacore experiment assessing affinity of C1q-DNA interaction and Dr. Ben King for language revision of the manuscript.

FOOTNOTES

*This work was supported by grants from the Söderberg Foundation, the Swedish Research Council (K2009-68X-14928-06-3), the Swedish Foundation for Strategic Research, the Swedish Rheumatism Association, the National Board of Health and Welfare and Skåne University Hospital, as well as Österlund, Greta and Johan Kock, King Gustaf V's 80th Birthday, Knut and Alice Wallenberg, Inga-Britt and Arne Lundberg Foundations. MM was supported by a postdoctoral stipend from the Crafoord Foundation.

^aAll abbreviations used: A2, annexin A2; A5, annexin A5; α 1-AT, α 1-antitrypsin; AF, Alexa Fluor; C4BP, C4b-binding protein; CRP, C-reactive protein; FH, factor H; Hi-NHS, heat inactivated normal human serum; HRP, horse radish peroxidase; NHS, normal human serum; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; SLE, systemic lupus erythematosus

FIGURE LEGENDS

Figure 1. *C1q binds DNA and histones.* **A)** Increasing concentrations of C1q were flown over immobilized biotinylated DNA on a plasmon surface resonance (Biacore) streptavidin chip. Dose dependent binding of C1q to DNA was observed and is presented in arbitrary response units (RU). **B)**

The response obtained at equilibrium was plotted against C1q concentration and K_D value of the C1q DNA interaction was determined to 2.2×10^{-8} M. **C)** By flow cytometry, dsDNA expression and C1q binding (50 μ g/ml) on apoptotic cells were investigated after indicated time of apoptosis induction. An increase of expression of dsDNA as well as binding of C1q was seen during the course of apoptosis although the increase was more pronounced for dsDNA than the C1q binding. **D)** Localization of C1q (blue), dsDNA (green) and PI (red) on apoptotic cells was analyzed using confocal microscopy. **E)** Binding of C1q to immobilized histones, IgG (positive control) and α 1-AT (negative control) was analyzed in an ELISA setup. Clear concentration dependent binding was seen for C1q to both histone complexes. **F)** Binding of C1q from Hi-NHS to immobilized histones or IgG was detected and compared to α 1-AT as a control. **G-H)** Radiolabeled histone H2A/H2B+H1 and H3/H4 were incubated with immobilized C1q, C1q globular heads, C1q collagenous tails and BSA (negative control). After washing, the amount of bound protein was determined in a γ -counter. Binding occurs mainly to the collagenous tail region. **I-J)** C4b deposition on immobilized histones or controls was measured from NHS (I), C1q deficient sera or C1q deficient sera reconstituted with 70 μ g/ml C1q (J). Deposition of C4b was detected on all histone complexes from NHS and it was decreased in C1q deficient sera but could only be restored upon addition of C1q to the H3/H4 histone complex. For C, representative values from two independent experiments are shown. For D, one representative image of two independent experiments is shown. For E-H, values are shown as mean of duplicates, $n = 4$ (G-H) and $n = 3$ (E-F, I-J) \pm standard deviation (SD). Significance of differences was calculated using one way ANOVA followed by Tukey's (G-H) or Dunnett's (F, J) Multiple Comparison post test and is displayed as; *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$.

Figure 2. Annexin A2 and A5 bind C1q and activate complement. A-B) Increasing concentrations of C1q were incubated with immobilized annexin A2, annexin A5, IgG (positive control) or α 1-AT (negative control). Clear binding to both annexins was seen both by purified protein (A) and from NHS (B). **C-D)** C1q (10 μ g/ml) diluted in buffers with increasing ionic strength or containing 5 mM or 20 mM EDTA was added to immobilized annexins. The interaction of C1q with both annexin A2 and annexin A5 decreased with increasing ionic strength (C) but was not dependent on bivalent cations (D). **E-F)** Radiolabeled annexin A2 and A5 were incubated with immobilized C1q, C1q globular heads, C1q collagenous tails and α 1-AT (negative control). After washing, the amount of bound protein was determined in a γ -counter. The annexins bound well to the collagenous tail region of C1q and annexin A5 also bound strongly to the globular head domain of C1q. **G-H)** Binding of C1q (6.25 μ g/ml) to annexin A2 was competed with FH (G) and reverse (5 μ g/ml fH, H). The actual concentration of each protein is depicted in nM in parentheses. No competition was observed in either setting. **I-J)** C4b deposition was measured on annexins or controls from NHS (I), C1q deficient sera or C1q deficient sera reconstituted with 70 μ g/ml C1q (J). Clear deposition was seen from NHS which was completely abolished in C1q deficient sera and could be restored upon addition of C1q. Values are shown as mean of duplicates, $n = 3$ (E, $n = 4$) \pm SD. For E-H, significance of differences was calculated using one way ANOVA followed by Tukey's multiple comparisons post test and is displayed as; *: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$. For J, significance of differences was calculated using two way ANOVA with a Bonferroni post test and is displayed as; ***: $p < 0.001$.

Figure 3. C1q binds to apoptotic T- and B-cells and interacts with annexin A2 and A5 exposed on the cell surface. A-B) Binding curves of C1q to apoptotic Jurkat T-cells and apoptotic Namalwa B-cells were obtained at different temperatures. C1q bound dose-dependently to both cell lines. **C)** Binding of C1q to apoptotic Jurkat T-cells and apoptotic primary T-lymphocytes. C1q bound dose-dependently, but reached lower levels for primary T-lymphocytes compared to Jurkat T-cells. **D)** Change in annexin A5 and A2 expression on the surface of apoptotic Jurkat T-cells expressed relative to antibody controls. Both annexin A2 and A5 expressions increased during the course of apoptosis induction. **E-F)** Pre-incubation of annexin A2 (E) and annexin A5 (F) increased binding of C1q (25 μ g/ml) to apoptotic Jurkat T-cells. The Δ GeoMean for the binding of C1q in the absence of competitor was defined as 1 and the binding in the presence of competitor has been calculated in relation. The actual concentration of each protein is depicted in nM in parentheses. A-C, values are shown as mean of three independent experiments, $n = 3 \pm$ SD. Values were normalized to binding for

200 $\mu\text{g/ml}$ of C1q at 37°C for 30 min. For D, representative values from two independent experiments are shown. For E-F, values are shown as mean of three independent experiments, $n = 3 \pm \text{SD}$. Significance of differences was calculated using one way ANOVA followed by Dunnett's Multiple Comparison post test and is displayed as; n.s.: not significant; **: $p < 0.01$.

Figure 4. *C1q, C4BP and FH do not bind the same surface ligand on apoptotic cells.* **A-E)** C4BP, C1q and FH were allowed to compete with one another for binding to apoptotic cells in 0, 5 and 25 molar ratios, whereby the protein and potential competitor had been pre-incubated for 30 min at RT before the addition to the cells. Binding of C4BP (25 $\mu\text{g/ml}$) was competed out by annexin A5 (A) whereas no competition was seen for any of the other proteins; C1q binding (25 $\mu\text{g/ml}$) by C4BP (B), C1q binding (25 $\mu\text{g/ml}$) by FH (C), C4BP binding (15 $\mu\text{g/ml}$) by C1q (D) or FH (5 $\mu\text{g/ml}$) binding by C1q (E). Data is presented as mean of three independent experiments, $n = 3 \pm \text{S.D}$. Significance of differences was calculated using one way ANOVA followed by Dunett's Multiple Comparison post test and is displayed as; *: $p < 0.05$; **: $p < 0.01$.

Figure 5. *C4BP binds both synthetic and natural PS incorporated in liposomes and on apoptotic cells.* **A-B)** Binding of C4BP to extruded PS-PC liposomes generated with natural (A) and synthetic (B) lipids was assayed using surface plasmon resonance. The response obtained at equilibrium was plotted against C4BP concentrations and K_D value of the interaction was determined to $1.09 \times 10^{-7} \text{M}$ for natural lipids and $1.93 \times 10^{-7} \text{M}$ for synthetic lipids. **C)** Binding of C4BP to PC liposomes containing PS, oxidized PS as well as lysoPS was assayed (nat: natural; syn: synthetic). **D)** Binding of AF488-labeled C4BP (50 $\mu\text{g/ml}$) and AF488-labeled C1q (150 $\mu\text{g/ml}$) to sonicated liposomes containing PC and PE with or without PS was assayed using flow cytometry. **E)** Localizations of AF488-labeled C1q (green), PS (blue, detected with AF647-labeled annexin A5) and PI (red) on apoptotic cells were studied using confocal microscopy and co-localization was calculated according to Manders. For D, values are shown as mean of three independent experiments, $n = 3 \pm \text{SD}$. Significance of differences was calculated using Welch's t-test assuming equal SD and is displayed as; *: $p < 0.05$. For E, one representative image of two independent experiments is shown.

Figure 6. *C4BP, C1q and FH bind to apoptotic cells generated by different apoptosis inducers.* **A-C)** Jurkat T-cells were rendered apoptotic with different extrinsic and intrinsic apoptosis inducers and the binding of 50 $\mu\text{g/ml}$ DyLight 488-labeled C4BP (A), C1q (B) and FH (C) was investigated. All proteins bound to the cells induced to become apoptotic with various agents, although the binding intensity differed for the individual inducers. Generally, all three proteins bound strongest to the staurosporine-induced cells. The percentage of early apoptotic cells generated in the experiments is indicated beside the flow cytometric histograms. The dot plots display the live (A5-/Via-Probe-), early (A5+/Via-Probe-) and late apoptotic (A5+/Via-Probe+) population of the cells that bound with high (red), middle (yellow) or low (green) intensity to the staurosporine-induced cells. **D)** Percentage of live, early and late apoptotic cells for all different apoptosis inducers. All inducers, except for staurosporine, generated populations that contained 30 – 60% live cells and 10% late apoptotic cells. Staurosporine-generated apoptotic population contained only 10% live but 40% late apoptotic cells. All inducers generated 30 – 60% early apoptotic cells. For A-C, representative histograms and dot plots of two independent experiments performed in duplicates in which the binding was once detected with labeled proteins (shown data) and once with FITC-labeled antibodies (data not shown) are presented. For D, the mean and SD for the cells treated with DyLight 488-labeled C4BP, C1q and FH are shown.

TABLES

Table 1. List of phospholipids used for surface plasmon resonance and flow cytometric analyses. C1q did not interact with any of the tested phospholipids.

Lipid Abbreviation	Lipid (underlined)	Lipid Source	Mol %	Treatments
<u>PC</u>	1-palmitoyl-2-oleoyl- <i>sn</i> -glycero-3-phosphocholine	Synthetic	100	-
<u>PS/PC</u>	1-palmitoyl-2-oleoyl- <i>sn</i> -glycero-3-phospho-L-serine	Synthetic	10/90	-
<u>PE/PC</u>	1-palmitoyl-2-oleoyl- <i>sn</i> -glycero-3-phosphoethanolamine	Synthetic	10/90	-
<u>LysoPC/PC</u>	1-oleoyl-2-hydroxy- <i>sn</i> -glycero-3-phosphocholine	Synthetic	3/97	-
LysoPC/PC			10/90	-
LysoPC/PC			60/40	-
<u>LysoPS/PC</u>	1-oleoyl-2-hydroxy- <i>sn</i> -glycero-3-phospho-L-serine	Synthetic	60/40	-
<u>LysoPE/PC</u>	1-oleoyl-2-hydroxy- <i>sn</i> -glycero-3-phosphoethanolamine	Synthetic	60/40	-
LysoPS/PC			10/90	-
PC			100	Oxidized
LysoPC/PC			40/60	Oxidized
LysoPC/PC			40/60	-
PS/PC			10/90	Oxidized
LysoPS/PC			10/90	Oxidized
<u>Natural PC</u>	<u>L-α-phosphatidylcholine</u>	Egg, chicken	100	-
<u>Natural PS/natural PC</u>	<u>L-α-phosphatidylserine</u>	Brain, porcine	10/90	-
<u>Natural LysoPC/natural PC</u>	<u>L-α-lysophosphatidylcholine</u>	Egg, chicken	20/80	-


Fig. 1 Martin *et al.*


Fig. 2 Martin *et al.*


Fig. 3 Martin *et al.*


Fig. 4 Martin *et al.*


Fig. 5 Martin *et al.*

Fig. 6 Martin *et al.*